# Hypoparathyroidism

Confirm true hypocalcemia with an inappropriately low PTH, correct reversible magnesium or vitamin D abnormalities, stabilize symptomatic patients promptly, and manage chronic disease to control symptoms without creating hypercalciuria, renal injury, or calcium-phosphate complications.

**Clinical question:** How should physicians confirm, stabilize, treat, and monitor acute and chronic hypoparathyroidism?

Updated: 2026-09-16T00:24:10.932302+00:00

## What matters in practice
- Diagnose hypoparathyroidism only when low ionized or albumin-corrected calcium occurs with a low or inappropriately normal intact PTH; measure magnesium and 25-hydroxyvitamin D concurrently to identify reversible functional suppression or competing causes. [2][13][16]
- Treat symptomatic hypocalcemia or profound asymptomatic hypocalcemia with corrected calcium below 1.9 mmol/L using prompt intravenous calcium, then transition to oral calcium plus an activated vitamin D metabolite. [16]
- For chronic disease, titrate calcium and active vitamin D to a low-normal or just-below-normal serum calcium target rather than high-normal calcium, which increases hypercalciuria and renal risk. [18][19][20]
- An elevated PTH with hypocalcemia and hyperphosphatemia is PTH resistance, not gland failure; exclude renal insufficiency and hypomagnesemia and pursue molecular or epigenetic evaluation when pseudohypoparathyroidism is suspected. [13][14]
- Monitor serum calcium, phosphate, magnesium, renal function, and urinary calcium; add sodium restriction and a thiazide-type diuretic when hypercalciuria persists during conventional treatment. [17][18][20]
- Reserve PTH replacement for chronic patients not adequately controlled with calcium and active vitamin D; historical rhPTH(1-84) labeling restricted use to patients inadequately controlled on conventional therapy and cautioned against osteosarcoma-risk settings. [1][11]

## Confirm the biochemical diagnosis and identify patients needing urgent calcium

Separate true PTH deficiency from functional suppression, PTH resistance, and non-PTH-mediated hypocalcemia before labeling chronic disease.

Obtain ionized calcium or albumin-corrected total calcium and intact PTH together. Hypoparathyroidism requires hypocalcemia with a low or inappropriately normal PTH; hyperphosphatemia supports the diagnosis but is not sufficient alone. Order serum phosphate, magnesium, creatinine or estimated GFR, and 25-hydroxyvitamin D at the same evaluation. [2][13][16]

Treat neuromuscular irritability, seizures, or other symptomatic hypocalcemia promptly with calcium replacement under careful monitoring; use intravenous calcium for symptomatic disease or profound asymptomatic hypocalcemia with corrected calcium below 1.9 mmol/L, then establish oral calcium and activated vitamin D therapy. Replace magnesium when low because normal magnesium is required for normal PTH secretion. [2][16][17]

Obtain an ECG when clinically significant hypocalcemia is suspected or symptoms are severe; hypocalcemia can prolong the QT interval. Do not delay calcium replacement for completion of etiologic testing in a symptomatic patient. [8]
- Low calcium plus low or inappropriately normal PTH: proceed as hypoparathyroidism after assessing magnesium, vitamin D status, renal function, and cause. [2][13][16]
- Low calcium plus elevated PTH: evaluate for PTH resistance, vitamin D deficiency, chronic kidney disease, or other secondary hyperparathyroid states rather than primary hypoparathyroidism. [13][14][15][16]
- Low magnesium: correct magnesium and reassess calcium and PTH before diagnosing irreversible parathyroid failure. [2][16][17]

*Biochemical patterns that redirect the hypocalcemia workup. [2][13][14][15][16]*

| Calcium/PTH pattern | Key accompanying findings | Interpretation and next action |
| --- | --- | --- |
| Low calcium; low or inappropriately normal PTH | Often high phosphate; assess magnesium, 25-hydroxyvitamin D, and renal function. [2][13][16] | Hypoparathyroidism or functional PTH suppression; correct hypomagnesemia and define surgical versus nonsurgical etiology. [2][16][17] |
| Low calcium; elevated PTH | Hyperphosphatemia with normal renal function and normal 25-hydroxyvitamin D supports PTH resistance. [13][14] | Suspect pseudohypoparathyroidism; exclude renal insufficiency and hypomagnesemia, assess phenotype and family history, and obtain targeted molecular or epigenetic testing. [13][14] |
| Low 25-hydroxyvitamin D with low calcium | Vitamin D deficiency classically produces an elevated PTH and subsequently low phosphorus from PTH-mediated phosphaturia. [15] | Treat vitamin D inadequacy and avoid misclassifying secondary hyperparathyroidism as PTH resistance or gland failure. [15] |

## Distinguish postsurgical disease from nonsurgical hypoparathyroidism

The operative history usually determines the first etiologic branch; absent that history, prioritize autoimmune, genetic, infiltrative, and magnesium-related causes.

Prior anterior neck surgery is the dominant clinical clue: approximately 75% of hypoparathyroidism is postsurgical, whereas about 25% is nonsurgical. Document the procedure, timing, prior calcium and PTH results, and ongoing requirement for calcium or activated vitamin D. [18]

Persistent low intact PTH with hypocalcemia requiring treatment for at least 6 months after surgery is commonly considered permanent postsurgical hypoparathyroidism, although some guidelines use 12 months. Continue reassessment during this interval rather than assuming permanent loss immediately after surgery. [2][3]

In patients without anterior neck surgery, elicit personal and family history of autoimmune disease, congenital syndromic features, childhood onset, or affected relatives. Autoimmune disease and genetic mutations are prominent nonsurgical causes; genetic testing is advised for an unknown cause, especially in patients younger than 40 years with syndromic features. [7][11][16]
- Review medications and clinical circumstances associated with hypomagnesemia or hypermagnesemia because either can impair PTH secretion. [16]
- Consider autoimmune hypoparathyroidism when no surgical explanation exists; AIRE-related failure of central tolerance is implicated in autoimmune disease. [13]
- For suspected infiltrative or destructive disease, direct further evaluation to the clinical context rather than using routine imaging as a diagnostic substitute for the calcium-PTH pattern. [16]

### When elevated PTH changes the diagnosis

Pseudohypoparathyroidism is characterized by end-organ PTH resistance: hypocalcemia, hyperphosphatemia, and elevated PTH despite normal renal function. The phenotype of Albright hereditary osteodystrophy—short stature, brachydactyly, subcutaneous calcifications, growth impairment, and obesity—supports a GNAS-related disorder, but phenotype may be variable. [13][14]
- Check calcium, phosphate, PTH, and 25-hydroxyvitamin D together; rule out renal insufficiency and hypomagnesemia before assigning a diagnosis of PTH resistance. [14]
- A synthetic PTH challenge (Ellsworth-Howard test) can be performed but is not required for diagnosis; molecular and epigenetic testing provides diagnostic refinement. [8][14]
- In PHP1, monitor PTH, calcium, phosphate, TSH, and urine calcium-to-creatinine ratio annually. [14]

*Etiologic clues that determine the next diagnostic action. [2][7][11][13][14][16][18]*

| Clinical setting | Most informative discriminator | Next action |
| --- | --- | --- |
| After thyroid, parathyroid, or other anterior neck surgery | Low or inappropriately normal PTH with hypocalcemia; establish duration of treatment dependence. [2][18] | Manage as postsurgical disease; reassess recovery before designating permanence, recognizing 6- and 12-month definitions are both used. [2][3] |
| No surgical history; early onset, family history, or syndromic findings | Unknown etiology, especially age younger than 40 years with syndromic features. [11] | Obtain genetic testing and assess for associated genetic disease. [7][11] |
| Hypocalcemia with high PTH and high phosphate | Normal renal function and normal 25-hydroxyvitamin D increase suspicion for PTH resistance. [13][14] | Evaluate for pseudohypoparathyroidism and obtain targeted molecular or epigenetic testing. [14] |
| Hypocalcemia with low magnesium | Magnesium deficiency can impair PTH secretion. [16][17] | Replete magnesium, then reassess calcium-PTH physiology before assigning chronic gland failure. [2][17] |

## Use calcium and active vitamin D to control symptoms without overshooting calcium

Conventional therapy remains first-line; dose to clinical and renal safety targets rather than to a high-normal serum calcium value.

Use oral calcium supplementation plus an activated vitamin D analogue as first-line chronic therapy. The treatment target is serum calcium in the low-normal range or just below the laboratory reference range, with normalization of serum phosphate, magnesium, and urine calcium when achievable. [11][18][20]

Select calcium formulation according to absorption conditions: calcium carbonate should be taken with food and requires an acidic gastric environment, whereas calcium citrate is absorbed without gastric acid and is preferred when gastric acid secretion is low. Correct low magnesium concurrently. [17]

Avoid pursuing upper-normal calcium solely to normalize the laboratory value. Serum calcium in the upper normal range increases hypercalciuria in the absence of PTH-mediated renal calcium reabsorption and can promote nephrolithiasis, nephrocalcinosis, and renal damage. [19][20]
- Assess symptoms together with calcium values: some patients remain symptomatic at low-normal calcium, whereas others experience hypercalcemia symptoms at high-normal calcium; individualize the target while avoiding unnecessary elevation. [20]
- Follow serum phosphate and urinary calcium during conventional therapy; reducing calcium or calcitriol may be necessary when these remain elevated. [18]
- Aim to avoid a calcium-phosphorus product near or above 55 mg2/dL2 because chronically elevated phosphate with this degree of product elevation is associated with ectopic soft-tissue calcification. [19]

### Address hypercalciuria before accepting renal injury

Loss of PTH-mediated tubular calcium reabsorption predisposes treated patients to hypercalciuria. If urinary calcium remains elevated while calcium and calcitriol are required, add dietary sodium restriction and consider a thiazide-type diuretic such as hydrochlorothiazide, chlorthalidone, or indapamide. [17]
- Obtain 24-hour urine calcium and creatinine every 6 to 12 months during chronic conventional treatment. [17]
- Monitor kidney function because impaired renal function is a common long-term complication and has been associated with disease duration and hypercalcemia during treatment. [17]

*Chronic conventional-management targets and surveillance. [17][18][19][20]*

| Parameter | Practical target or interval | Management consequence |
| --- | --- | --- |
| Serum calcium | Low-normal or just below the reference range; approximately 8.0-9.0 mg/dL is a chronic hypocalcemia target described in Endotext. [18][19][20] | Avoid high-normal calcium because it increases hypercalciuria and renal complications. [19][20] |
| Serum phosphate and magnesium | Normalize when possible; measure during conventional treatment. [18] | Adjust calcium and active vitamin D exposure as needed and correct magnesium abnormalities. [17][18] |
| Serum calcium and phosphate after a stable regimen | Every 3-6 months. [20] | Detect hypo- or hypercalcemia and persistent hyperphosphatemia before complications develop. [20] |
| Urinary calcium excretion | At least yearly; 24-hour urine calcium and creatinine every 6-12 months is also described. [17][20] | If elevated, review calcium/calcitriol exposure, restrict sodium, and consider a thiazide-type diuretic. [17] |

## Select PTH replacement for inadequately controlled chronic disease

Consider replacement when conventional therapy cannot achieve biochemical control and acceptable symptom burden without excessive treatment burden or renal risk.

Conventional therapy is first-line, but PTH replacement is an option for adults with chronic hypoparathyroidism who remain inadequately controlled. Conventional-treatment limitations include serum calcium fluctuation, high pill burden, poor quality of life, hypercalciuria, and renal complications. [11][18]

Historical FDA labeling for rhPTH(1-84) (NATPARA) limited use to an adjunct to calcium and vitamin D in patients who cannot be well controlled on conventional therapy. The label warned of potential osteosarcoma risk and advised avoiding use in patients with Paget disease, unexplained alkaline phosphatase elevation, open epiphyses, hereditary osteosarcoma-predisposition syndromes, or prior skeletal external-beam or implant radiation. [1]

Palopegteriparatide is available for adults with hypoparathyroidism and has been reported to normalize serum calcium, phosphorus, and urine calcium and improve quality of life. Initiation and titration require monitoring of calcium, phosphate, urinary calcium, renal function, and concurrent calcium and active vitamin D requirements; do not use historical rhPTH(1-84) dosing data to dose another product. [11][20][21]
- Review baseline serum calcium, phosphate, magnesium, renal function, 25-hydroxyvitamin D, and urine calcium before changing chronic therapy. [17][18][20]
- After a stable PTH-replacement regimen is reached, monitor serum calcium and phosphate every 3-6 months and urinary calcium at least yearly. [20]
- Expect both directions of calcium excursion during PTH therapy: rhPTH(1-84) trials reported hypercalcemia and hypocalcemia, supporting active titration rather than fixed-dose assumptions. [18]

*When to remain on conventional treatment versus escalate to PTH replacement. [1][11][18][20]*

| Clinical state | Preferred approach | Key safety issue |
| --- | --- | --- |
| Symptoms and biochemical targets controlled with tolerable oral calcium plus active vitamin D | Continue conventional therapy with calcium, phosphate, renal, and urinary calcium surveillance. [11][18][20] | Avoid high-normal serum calcium and detect hypercalciuria before nephrolithiasis or nephrocalcinosis occurs. [17][19] |
| Persistent fluctuations, excessive pill burden, poor quality of life, hypercalciuria, or renal complications despite conventional therapy | Consider PTH replacement in an adult with chronic hypoparathyroidism; monitor and titrate concurrent supplementation. [11][18][20] | Monitor for hypo- and hypercalcemia during titration. [18] |
| Considering historical rhPTH(1-84) in a patient with osteosarcoma-risk factors | Avoid NATPARA in specified high-risk settings. [1] | Risk factors include Paget disease, unexplained alkaline phosphatase elevation, open epiphyses, hereditary predisposition, and prior skeletal radiation. [1] |

## Monitor renal and calcium-phosphate complications throughout chronic disease

Long-term follow-up should detect treatment-related renal injury and biochemical exposure before irreversible complications occur.

Renal complications are central to chronic management because absent PTH reduces tubular calcium reabsorption and conventional calcium-calcitriol therapy can further increase urinary calcium. Nephrolithiasis and nephrocalcinosis may occur with overtreatment; chronic kidney disease stage 3 or higher has been reported at rates 2- to 17-fold higher than in normal controls in one review. [17]

At each maintenance review, integrate symptoms with serum calcium, phosphate, magnesium, renal function, and urinary calcium rather than adjusting therapy from serum calcium alone. High calcium-phosphorus exposure increases concern for ectopic calcification, while low calcium targets that leave ongoing symptoms justify individualized adjustment or consideration of PTH replacement. [18][19][20]

In chronic postsurgical disease, the diagnosis itself warrants surveillance for multisystem complications. For nonsurgical and genetic disease, pair biochemical follow-up with cause-specific assessment, including thyroid testing in PHP1 because multihormone resistance can occur. [11][14]
- Recheck serum calcium and phosphate every 3-6 months once stable; shorten the interval after a regimen change or clinically meaningful calcium excursion. [20]
- Obtain urinary calcium at least annually and more often within the 6- to 12-month interval used for 24-hour urine calcium and creatinine monitoring when hypercalciuria is a concern. [17][20]
- Escalate chronic management when serum calcium control depends on high exposure to calcium or active vitamin D, urinary calcium remains elevated, kidney function declines, or the patient remains symptomatic despite low-normal calcium. [11][17][18][20]

*Triggers for chronic-treatment reassessment. [11][17][18][19][20]*

| Trigger | Likely concern | Immediate reassessment |
| --- | --- | --- |
| High-normal or recurrently elevated serum calcium | Hypercalciuria, nephrolithiasis, nephrocalcinosis, or renal injury risk. [17][19][20] | Review calcium and active vitamin D exposure; measure urinary calcium and renal function. [17][18] |
| Persistent hyperphosphatemia or calcium-phosphorus product near 55 mg2/dL2 | Risk of ectopic soft-tissue calcification. [19] | Review calcium and active vitamin D dosing and repeat calcium-phosphate assessment. [18][19] |
| Persistent symptoms at a low-normal calcium concentration | Individual calcium sensitivity or inadequately controlled disease. [20] | Confirm magnesium, phosphate, vitamin D status, adherence and urinary calcium; individualize target or consider escalation. [17][18][20] |
| Declining renal function or recurrent stone disease | Long-term renal complication of disease and treatment. [17] | Quantify urinary calcium, avoid unnecessary hypercalcemia, and consider sodium restriction, thiazide therapy, or PTH-replacement evaluation. [17][18] |

## References
1. This label may not be the latest approved by FDA. For current ... — www.accessdata.fda.gov — https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125511s020lbl.pdf
2. Hypoparathyroidism - Symptoms, diagnosis and treatment | BMJ Best Practice — bestpractice.bmj.com — https://bestpractice.bmj.com/topics/en-gb/132
3. Hypoparathyroidism - Symptoms, diagnosis and treatment | BMJ Best Practice US — bestpractice.bmj.com — https://bestpractice.bmj.com/topics/en-gb/132?locale=ko
4. Efficacy and Safety of Parathyroid Hormone Replacement With ... — onlinelibrary.wiley.com — https://onlinelibrary.wiley.com/doi/full/10.1002/jbmr.4726
5. Evaluation and Management of Hypoparathyroidism Summary ... — onlinelibrary.wiley.com — https://onlinelibrary.wiley.com/doi/10.1002/jbmr.4691
6. UK national chronic hypoparathyroidism audit - Wiley Online Library — onlinelibrary.wiley.com — https://onlinelibrary.wiley.com/doi/full/10.1111/cen.14798
7. Management of Hypoparathyroidism - Wiley Online Library — onlinelibrary.wiley.com — https://onlinelibrary.wiley.com/doi/pdf/10.1002%2Fjbmr.4716
8. Hypoparathyroidism - an overview | ScienceDirect Topics — www.sciencedirect.com — https://www.sciencedirect.com/topics/medicine-and-dentistry/hypoparathyroidism
9. Disorders of Calcium Metabolism - an overview — www.sciencedirect.com — https://www.sciencedirect.com/topics/biochemistry-genetics-and-molecular-biology/disorders-of-calcium-metabolism
10. Calcium Urine Level - an overview | ScienceDirect Topics — www.sciencedirect.com — https://www.sciencedirect.com/topics/biochemistry-genetics-and-molecular-biology/calcium-urine-level
11. Best practice recommendations for the diagnosis and management of hypoparathyroidism - ScienceDirect — www.sciencedirect.com — https://www.sciencedirect.com/science/article/abs/pii/S0026049525002045
12. Pseudohypoparathyroidism with normocalcemia: a rare case... : Annals of Medicine and Surgery — journals.lww.com — https://journals.lww.com/annals-of-medicine-and-surgery/fulltext/2025/07000/pseudohypoparathyroidism_with_normocalcemia__a.73.aspx
13. Hypocalcemia: Diagnosis and Treatment - Endotext - NCBI Bookshelf — www.ncbi.nlm.nih.gov — http://www.ncbi.nlm.nih.gov/books/NBK279022
14. Pseudohypoparathyroidism and Related Disorders - StatPearls - NCBI Bookshelf — www.ncbi.nlm.nih.gov — https://www.ncbi.nlm.nih.gov/books/NBK547709
15. Index of Suspicion In the Nursery | NeoReviews | American Academy of Pediatrics — publications.aap.org — https://publications.aap.org/neoreviews/article/5/8/e356/87025/Index-of-Suspicion-In-the-Nursery
16. Hypoparathyroidism - PubMed — www.ncbi.nlm.nih.gov — http://www.ncbi.nlm.nih.gov/pubmed/22863393
17. Review of Hypoparathyroidism — pmc.ncbi.nlm.nih.gov — https://pmc.ncbi.nlm.nih.gov/articles/PMC5237638
18. Management of Hypoparathyroidism - PMC — pmc.ncbi.nlm.nih.gov — https://pmc.ncbi.nlm.nih.gov/articles/PMC13202617
19. Hypocalcemia - Endotext - NCBI Bookshelf — www.ncbi.nlm.nih.gov — https://www.ncbi.nlm.nih.gov/books/NBK344077
20. Management of Hypoparathyroidism: Present and Future - PMC — pmc.ncbi.nlm.nih.gov — https://pmc.ncbi.nlm.nih.gov/articles/PMC5393596
21. Multicenter retro-prospective observational study on chronic hypoparathyroidism and rhPTH (1–84) treatment — pmc.ncbi.nlm.nih.gov — https://pmc.ncbi.nlm.nih.gov/articles/PMC9360119
22. [PDF] Hypoparathyroidism 2025 Summit - Endocrine Society — www.endocrine.org — https://www.endocrine.org/-/media/endocrine/files/endo-2025/agenda_parathyroid-summit_15may2025_posting.pdf
23. Detailed Schedule — endo2026.endocrine.org — https://endo2026.endocrine.org/agenda.asp?startdate=6%2F14%2F2026&enddate=6%2F14%2F2026&BCFO=&pfp=FullSchedule&fa=&fb=&fc=&fd=
24. Management of Hypoparathyroidism - Khan - 2022 — onlinelibrary.wiley.com — https://onlinelibrary.wiley.com/doi/10.1002/jbmr.4716

## Editorial note

Prepared from cited clinical literature using Astra's research workflow. Verify recommendations against current guidance and patient-specific factors.